BR112014018795A2 - derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase - Google Patents

derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase

Info

Publication number
BR112014018795A2
BR112014018795A2 BR112014018795A BR112014018795A BR112014018795A2 BR 112014018795 A2 BR112014018795 A2 BR 112014018795A2 BR 112014018795 A BR112014018795 A BR 112014018795A BR 112014018795 A BR112014018795 A BR 112014018795A BR 112014018795 A2 BR112014018795 A2 BR 112014018795A2
Authority
BR
Brazil
Prior art keywords
pyrrolo
kinase inhibitors
pyridine derivatives
present
relates
Prior art date
Application number
BR112014018795A
Other languages
English (en)
Other versions
BR112014018795B1 (pt
Inventor
John Graham Christoper
Jayne Stefaniak Emma
Stokes Stephen
Christopher Ray Stuart
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of BR112014018795A2 publication Critical patent/BR112014018795A2/pt
Publication of BR112014018795B1 publication Critical patent/BR112014018795B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase". a presente invenção refere-se aos compostos de (i) e usos terapêuticos dos mesmos. (i) os termos z, y e r1 são como definidos de acordo com as reivindicações. a presente invenção refere-se ainda a uma composição farmacêutica compreendendo referido o composto e um ou mais veículos e/ou farmaceuticamente aceitáveis. ainda, o presente pedido de patente refere-se ao uso do referido composto em uma condição responsável pela inibição de atividade de proteína cinase.
BR112014018795-9A 2012-01-30 2013-01-30 Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase BR112014018795B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1201566.5 2012-01-30
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
BR112014018795A2 true BR112014018795A2 (pt) 2017-07-04
BR112014018795B1 BR112014018795B1 (pt) 2020-09-29

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018795-9A BR112014018795B1 (pt) 2012-01-30 2013-01-30 Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase

Country Status (21)

Country Link
US (3) US10000481B2 (pt)
EP (1) EP2809670B1 (pt)
JP (1) JP6199316B2 (pt)
CN (4) CN106866658B (pt)
AU (1) AU2013213954B2 (pt)
BR (1) BR112014018795B1 (pt)
CA (1) CA2862940C (pt)
DK (1) DK2809670T3 (pt)
EA (1) EA026657B1 (pt)
ES (1) ES2637340T3 (pt)
GB (1) GB201201566D0 (pt)
HK (1) HK1200447A1 (pt)
HU (1) HUE035332T2 (pt)
IL (1) IL233595B (pt)
IN (1) IN2014DN06104A (pt)
MX (1) MX352927B (pt)
NZ (1) NZ627361A (pt)
PL (1) PL2809670T3 (pt)
PT (1) PT2809670T (pt)
WO (1) WO2013114113A1 (pt)
ZA (1) ZA201405070B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
BR112014026367A2 (pt) * 2012-04-23 2017-06-27 Genentech Inc 5-bromo-4-cloro-3-nitro-1h-pirrol[2,3-b]piridina e seu processo
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
HUE049228T2 (hu) 2016-02-23 2020-09-28 Taiho Pharmaceutical Co Ltd Új kondenzált pirimidin vegyület vagy annak sója
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230250060A1 (en) * 2022-01-12 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
AU2004293026B2 (en) * 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
CA2711614A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
PT2294065E (pt) 2008-01-22 2014-05-15 Vernalis R&D Ltd Derivados de indolil-piridona com actividade inibidora de quinase 1 de ponto de controlo
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
BRPI0909957A2 (pt) * 2008-06-11 2016-04-19 Genentech Inc "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero"
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
IL233595B (en) 2018-05-31
US20180362526A1 (en) 2018-12-20
US20210206762A1 (en) 2021-07-08
CN104203948A (zh) 2014-12-10
CN111484493A (zh) 2020-08-04
PT2809670T (pt) 2017-08-23
IN2014DN06104A (pt) 2015-08-14
CA2862940C (en) 2021-09-14
PL2809670T3 (pl) 2017-10-31
CN106866658B (zh) 2021-04-27
JP2015505555A (ja) 2015-02-23
US10889582B2 (en) 2021-01-12
WO2013114113A1 (en) 2013-08-08
IL233595A0 (en) 2014-08-31
MX352927B (es) 2017-12-14
AU2013213954B2 (en) 2016-02-25
BR112014018795B1 (pt) 2020-09-29
HUE035332T2 (en) 2018-05-02
CN107011341A (zh) 2017-08-04
EP2809670A1 (en) 2014-12-10
US10000481B2 (en) 2018-06-19
MX2014009112A (es) 2014-11-10
DK2809670T3 (en) 2017-08-28
AU2013213954A1 (en) 2014-08-07
EP2809670B1 (en) 2017-05-17
NZ627361A (en) 2016-07-29
EA026657B1 (ru) 2017-05-31
US20150011533A1 (en) 2015-01-08
EA201491376A1 (ru) 2015-01-30
GB201201566D0 (en) 2012-03-14
HK1200447A1 (en) 2015-08-07
ES2637340T3 (es) 2017-10-11
CA2862940A1 (en) 2013-08-08
CN106866658A (zh) 2017-06-20
JP6199316B2 (ja) 2017-09-20
ZA201405070B (en) 2016-03-30

Similar Documents

Publication Publication Date Title
BR112014018795A2 (pt) derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
BR112014033055A8 (pt) Inibidores seletivos de delta pi3k
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112014022000A2 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
GB201104267D0 (en) Pyrrolopyridineamino derivatives
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
BR112015015653A8 (pt) composto, método de preparação dos compostos, composto para uso, composição farmacêutica e métodos in vitro
BR112015032902A8 (pt) compostos de heteroarila, seus usos e composições farmacêuticas
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
CA2920410C (en) Thienopiperidine derivative and use thereof
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2013, OBSERVADAS AS CONDICOES LEGAIS.